• McKesson (NYSE:MCK) supported new research presented at ASCO 2026 by The US Oncology Network.
• The study found that advanced practice provider led consult models can significantly improve patient access in community oncology.
• Findings also indicate higher physician capacity when these consult models are used in real world clinic settings.
• This is a fresh data point on how McKesson is involved in reshaping care delivery for cancer patients.

For investors tracking McKesson as more than a pharmaceutical distributor, this update sits within the broader healthcare services and oncology solutions story. The US Oncology Network research showcased at ASCO 2026 highlights how care models supported by McKesson intersect with long running trends in community based cancer care, such as pressure on physician time and the push to treat patients closer to home.

As payors, providers, and regulators continue to focus on access, capacity, and total cost of care, new models like advanced practice provider led consults may influence how oncology practices operate. For holders watching NYSE:MCK, this type of real world evidence relates to the wider question of how the company’s services footprint may shape its role across cancer care delivery over time.

Stay updated on the most important news stories for McKesson by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on McKesson.

Quick Assessment

• ✅ Price vs Analyst Target: At US$742.44, McKesson trades about 22% below the US$949.73 analyst price target.
• ❌ Simply Wall St Valuation: The stock is flagged as trading at a very large premium to the Simply Wall St fair value estimate.
• ❌ Recent Momentum: The share price has fallen 9.7% over the past 30 days.

There is only one way to know the right time to buy, sell or hold McKesson: review a detailed valuation. Head to Simply Wall St's company report for the latest analysis of McKesson's Fair Value.

Key Considerations

• 📊 The ASCO 2026 data reinforces McKesson’s role in community oncology services, which sits alongside its broader healthcare operations and revenue base.
• 📊 Watch how adoption of advanced practice provider led consult models feeds into physician capacity, patient volumes and any commentary on oncology solutions within future updates.
• ⚠️ Simply Wall St flags one risk related to a high level of debt, which investors may want to weigh against any growth in services linked to this research.

Dig Deeper

For the full picture, including more risks and potential rewards, check out the complete McKesson analysis. Alternatively, you can visit the community page for McKesson to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.